Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
September 26, 2022 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
August 30, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MD
August 15, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
August 10, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ISELIN, N.J., Aug. 10, 2022 (GLOBE...
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
August 04, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
July 05, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
June 14, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug Administration (FDA) ISELIN, N.J., June 14,...
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
May 31, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic...